Warfarin and Non-Steroidal Anti-Inflammatory Drugs (NSAID) Customized Alert

This study has been completed.
Sponsor:
Information provided by:
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00880932
First received: April 13, 2009
Last updated: NA
Last verified: April 2009
History: No changes posted
  Purpose

The hypothesis is that a newly formatted electronic alert that requires the prescriber to pause and enter a specific "reason for override" on this alert, will cause prescribers in the intervention group to be significantly less likely to prescribe the combination of warfarin and NSAID than prescribers in the control group.


Condition Intervention
Warfarin and NSAID
Behavioral: Electronic Alert

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Caregiver)
Official Title: The Effect of Customized Alerts Versus Generic Alerts for the Prescription of Warfarin and NSAID

Resource links provided by NLM:


Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Decreased rate of prescription of the combination of warfarin and NSAID [ Time Frame: 17 months ] [ Designated as safety issue: Yes ]

Enrollment: 1865
Study Start Date: August 2006
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: customized electronic alert
This intervention was not targeted to patients with a disease but to the providers. The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a "reason for override" whenever the combination drugs of warfarin and NSAID were ordered together.
Behavioral: Electronic Alert
No Intervention: Standard practice
The control group was not patients but the providers. Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.

  Eligibility

Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • All resident physicians (RP) and nurse practitioners (NP) involved in inpatient care at two hospitals of the University of Pennsylvania

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00880932

Locations
United States, Pennsylvania
Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center
Phila, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
  More Information

No publications provided

Responsible Party: UPenn School of Medicine
ClinicalTrials.gov Identifier: NCT00880932     History of Changes
Other Study ID Numbers: 803787
Study First Received: April 13, 2009
Last Updated: April 13, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pennsylvania:
warfarin
NSAID
The condition is the concomitant prescription of

Additional relevant MeSH terms:
Anti-Inflammatory Agents, Non-Steroidal
Warfarin
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anticoagulants
Antirheumatic Agents
Hematologic Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014